Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis

Clinical and Experimental Immunology

Volumn 118, Issue 1, 1999, Pages 137-146

  Hildner, K ^a   Finotto, S ^a   Becker, C ^a   Schlaak, J ^a   Schirmacher, P ^b   Galle, P R ^a   Marker Hermann E ^a   Neurath, Marcos F ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Immunosuppression; Methotrexate; Tumour necrosis factor

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR;

APOPTOSIS; ARTICLE; CARTILAGE DEGENERATION; CELL PROLIFERATION; COMPETITIVE INHIBITION; DRUG EFFECT; EFFECTOR CELL; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVIUM; T LYMPHOCYTE ACTIVATION; TARGET CELL;

ADULT; ANTIGENS, CD; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; MALE; METHOTREXATE; MIDDLE AGED; MONOCYTES; RECEPTORS, ANTIGEN, T-CELL; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032873598     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01022.x     Document Type: Article

References (48)

1. 1 Weinblatt ME, Kaplen H, Germain BF et al. Methotrexate in rheumatoid arthritis; a five year prospective multicenter study. Arthritis Rheum 1994; 37:1492-8.
2. 2 Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 1992; 35:138-45.
3. 3 Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312:88-92.
4. 4 Kavanaugh AF, Lipsky PE. Rheumatoid arthritis. In: Rich RR, eds. Clinical immunology. 1996:1093-106.
5. 5 Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144:3347-53.
6. 6 Baggott JE, Morgan SL, Koopman WJ. The effect of methotrexate and 7-hydroxymethotrexate on rat adjuvant arthritis and on urinary amino-imidazole carboxamide exeretion. Arthritis Rheum 1998; 41:1407-10.
7. 7 Kremer JM. Possible mechanisms of action of methotrexate in patients with rheumatoid arthritis. Br J Rheumatol 1995; 34 (Suppl. 2):26-29.
8. 8 Moreland LW, Heck LW Jr, Koopman WJ. Biologic agents for treating rheumatoid arthritis: concepts and progress. Arthritis Rheum 1997; 40:397-409.
9. 9 Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951-60.
10. 10 Segal R, Mozes E, Yaron M, Tartakovsky B. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989; 32:370-7.
11. 11 Hu SK, Mitcho YL, Oronsky AL, Kerwar SS. Studies on the effect of methotrexate on macrophage function. J Rheumatol 1988; 15:206-9.
12. 12 Meyer FA, Yaron I, Mashiah V, Yaron M. Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 1993; 20:238-42.
13. 13 Conolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T. Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int J Immunopharmacol 1988; 10:717-28.
14. 14 Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322-8.
15. 15 Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88:2441-5.
16. 16 Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanisms of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92:2675-82.
17. 17 Hirata S, Matsubara T, Saura R, Tateishi H, Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum 1989; 32:1065-73.
18. 18 Sperling RI, Coblyn JS, Larkin JK, Benincaso AI, Austen KF, Weinblatt ME. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 1990; 33:1149-55.
19. 19 Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1 -beta to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993; 31:667-74.
20. 20 Crilly A, McInnes IB, McDonald AG, Watson J, Capell HA, Madhok R. Interleukin-6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 1995; 22:224-6.
21. 21 Constantin A, Loubet P, Lambert N, Yassine B, Abbal M, Mazieres B, Preval C, Cantagrel A. Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1998; 41:48-57.
22. 22 Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ. Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 1995; 34:602-9.
23. 23 Brinkmann V, Kristotic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO-and CD45RO+ subsets. J Immunol 1995; 155:3322-8.
24. 24 Neurath MF, Pettersson S, Meyer zum Büschenfelde KH, Strober W. Local administration of antisense oligonucleotides to the p65 subunit of NF-kappaB abrogates experimental colitis in mice. Nature Med 1996; 2:998-1004.
25. 25 Amett FC, Edworthy SM, Bloch DA, McShane DJ, Fries FJ, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
26. 26 Sinnett MJ, Groff GD, Raddatz DA, Franck WA, Bertino J. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1989; 16:745-8.
27. 27 Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Ann Rev Immunol 1989; 7:625-55.
28. 28 Strober W, Kelsall BL, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath MF. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997; 18:61-64.
29. 29 Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. Transgenic mice expressing human tumour necrosis: a predictive genetic model of arthritis. EMBO J 1991; 10:4025-31.
30. 30 Brennan FM, Maini RN, Feldmann M. TNF-alpha: a pivotal role in rheumatoid arthritis. Br J Rheumatol 1993; 31:293-8.
31. 31 Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor -Fc fusion protein. N Engl J Med 1997; 337:141-7.
32. 32 Rankin ECC, Choy ESH, Kassimos D et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34:334-42.
33. 33 Elliott MJ, Maini RN, Feldmann M et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36:1681-90.
34. 34 Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
35. 35 Neurath MF, Hildner K, Becker C et al. Methotrcxate specifically modulates cytokine production by T cells and macrophages in collagen-induced arthritis. A mechanism for methotrexate-mediated immunosuppression. Clin Exp Immunol 1998; 115:42-55.
36. 36 Welles WL, Silkworth J, Oronsky AL, Kerwar SS, Galivan J. Studies on the effect of low dose methotrexate on rat adjuvant arthritis. J Rheumatol 1985; 12:904-6.
37. 37 Williams AS, Camilleri JP, Topley N, Williams BD, Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 1994; 32:53-58.
38. 38 Kohem CL, Brezinschek RI, Wisbey H, Tortorella C, Lipsky PE, Oppenheimer-Marks N. Enrichment of differentiated CD45RBdim, CD27-memory T cells in the peripheral blood, synovial fluid, and synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:844-54.
39. 39 Thomas R, McHraith M, Davis LS, Lipsky PE. Rheumatoid synovium is enriched in CD45RBdim mature memory T cells that are potent helpers for B cell differentiation. Arthritis Rheum 1992; 35:1455-65.
40. 40 Neighbour PA, Crayzel AI. Interferon production in vitro by leukocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. Clin Exp Immunol 1981; 45:576-82.
41. 41 Quayle AJ, Chomarat P, Miossee P, Kjeldsen-Kragh J, Forre O, Natvig JB. Rheumatoid inflammatory T-cell clones express mostly Th1 but also Th2 and mixed (Th0 like) cytokine patterns. Scand J Immunol 1993; 38:75-82.
42. 42 Miossec P, van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997; 40:2105-15.
43. 43 Barrera BR, Haagsma CJ, Boerbooms AM, Van Riel PL, Borm GF, Van dePutte LB, Van der Meer JW. Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists. Longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 1995; 34:747-55.
44. 44 Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AMM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39:1961-9.
45. 45 Davis LS, Schulze-Koops H, Lipsky PE. Rheumatoid synovial memory T cells have been primed in vivo to be interferon-gamma producers. Arthritis Rheum 1997; 40 (Suppl. 9):S119.
46. 46 Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41:1552-63.
47. 47 Mosmann T, Sad R. The expanding universe of T-cell subsets: TH1, TH2, and more. Immunol Today 1996; 17:138-46.
48. 48 Bologna C, Edno L, Anaya JM et al. Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum 1994; 37:1770-3.